Bayesian Capital Management’s Genmab GMAB Stock Holding History

Bayesian Capital Management’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$285K	Buy	+10,369	New	+$276K	0.18%	160
2024 Q2	–	Sell	-11,436	Closed	-$342K	–	886
2024 Q1	$342K	Buy	+11,436	New	+$336K	0.03%	523
2023 Q1	–	Sell	-12,466	Closed	-$528K	–	905
2022 Q4	$528K	Buy	+12,466	New	+$514K	0.08%	345
2022 Q2	–	Sell	-11,964	Closed	-$433K	–	894
2022 Q1	$433K	Buy	+11,964	New	+$411K	0.06%	414

Other funds holding GMAB

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bayesian Capital Management's GMAB Position: Q2 2026 in Review

Bayesian Capital Management opened a new position in Genmab (GMAB) in Q2 2026: 10,369 shares worth $285K. The stake represents 0.18% of the portfolio and ranks #160 among its holdings. This is a return to the name: Bayesian Capital Management previously reported a position in GMAB as recently as Q1 2024.

Bayesian Capital Management first reported a position in GMAB in Q1 2022 and has held it in 4 quarters since. The position peaked at $528K in Q4 2022. 292 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

Bayesian Capital Management held 10,369 shares of Genmab worth $285K as of Q2 2026.
Genmab was a new Bayesian Capital Management position in Q2 2026.
Genmab made up 0.18% of Bayesian Capital Management's portfolio in Q2 2026, its #160 holding.
Bayesian Capital Management first reported a position in Genmab in Q1 2022 and has held it in 4 quarters since.
Bayesian Capital Management's Genmab position peaked at $528K in Q4 2022.
292 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.